Want to see TOVX full AI Analyst Report?
TOVX Stock Chart & Stats
$0.22
>-$0.01(-4.44%)
At close: 4:00 PM EDT
$0.22
>-$0.01(-4.44%)
Day’s Range― - ―
52-Week Range$0.16 - $0.86
Previous Close$0.22
Volume479.63K
Average Volume (3M)8.88M
Market Cap
$9.80M
Enterprise Value-$2.70
Total Cash (Recent Filing)$14.43M
Total Debt (Recent Filing)$3.69M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding45,892,670
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.50Price Target Upside1036.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$29.37M
Bulls Say, Bears Say
Bulls Say
Clinical Validation (VCN-01)A peer-reviewed Phase 1 publication demonstrating survival signals and translational biomarkers materially reduces scientific risk. Durable impact: it validates the mechanism (stroma degradation, immune modulation), strengthens scientific credibility with clinicians and partners, and de-risks later-stage development and partnering discussions over the next several months.
Regulatory Progress (VIRAGE2 Start)National regulator authorization to begin VIRAGE2 shows regulatory acceptance of continued clinical exploration. Durable impact: it advances a clear development path to refine dosing and support potential pivotal design, leverages prior EMA/FDA recognition of benefit, and enhances attractiveness for strategic partnerships and future registrational planning.
Low Financial LeverageLow recorded debt provides structural financial flexibility for a cash-burning biotech. Durable impact: manageable leverage reduces near-term insolvency risk, makes equity or partnership financing more feasible, and gives the company room to prioritize R&D and clinical milestones without heavy interest burden over the coming quarters.
Bears Say
Sustained Cash BurnRepeated negative operating and free cash flow indicates ongoing reliance on external funding to sustain operations. Durable impact: continued cash burn increases dilution risk or forces asset-sales/partnerships to fund pivotal trials, constraining strategic optionality and raising execution risk over the next several months.
Minimal Recurring RevenueVery limited product or recurring revenue leaves the company dependent on financing and milestone/licensing events. Durable impact: absence of commercial cash flow means viability hinges on clinical success and fundraising ability, increasing vulnerability to trial setbacks and making multi-quarter planning uncertain.
Governance And Financing UncertaintyRepeated quorum failures create procedural delays around warrant approvals tied to financing arrangements. Durable impact: this injects timing uncertainty into a planned funding pathway, can delay access to committed capital or complicate investor relations, and raises execution risk for near-term financing and dilution outcomes.
Theriva Biologics News
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $0.16 and its highest was $0.86 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $9.80M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Aug 12, 2026 which is in 13 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on May 05, 2026. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.06.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 45,892,670 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went up 0.526%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
TOVX Stock 12 Month Forecast
Average Price Target
$2.50
▲(1036.36% Upside)
Technical Analysis
Ownership Overview
0.57%
Insiders
0.90% Mutual Funds
0.33% Other Institutional Investors
97.15% Public Companies and
Individual Investors